Skip to main content
OpenTrials
Completed

NCT Number: NCT02354651

Response to Diaphragmatic Pacing in Subjects With Pompe Disease

The purpose of this study is to determine the effect of diaphragm pacing on respiratory function in subjects with Pompe disease by evaluating the duration and pattern of spontaneous respiratory function versus paced ventilation respiratory function in patients with Pompe disease who have received the NeuDx Diaphragm pacer (DPS).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pompe Disease Brain Diseases Brain Diseases, Metabolic Brain Diseases, Metabolic, Inborn Carbohydrate Metabolism, Inborn Errors Central Nervous System Diseases Congenital, Hereditary, and Neonatal Diseases and Abnormalities Genetic Diseases, Inborn Glycogen Storage Disease Glycogen Storage Disease Type II Lysosomal Storage Diseases Lysosomal Storage Diseases, Nervous System Metabolic Diseases Metabolism, Inborn Errors Nervous System Diseases Nutritional and Metabolic Diseases

Age range

2 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Florida

Gainesville, Florida, 32610, United States

About this study

Subjects with Pompe disease who are scheduled to receive a NeuRx Diaphragm pacer (DPS) will be invited to participate in this study. The following tests will be performed during participation in the study:

  • Forced expiratory tests
  • Maximal Inspiratory Pressure (MIP)
  • Resting Breathing Pattern
  • Phrenic Nerve Function Evaluation with EMG
  • Severe Respiratory Insufficiency Questionnaire
  • Magnetic stimulation
  • Diaphragm conditioning consisting of:
  • The external stimulator settings
  • The duration of diaphragm stimulation
  • Off-ventilator spontaneous breathing (SB)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of Pompe disease as defined by mutational analysis, GAA enzyme activity assay in blood spot, and/or fibroblast culture less than 40% of control value
  • Medically and functionally eligible for NeuRx DPS implantation, as determined by a clinical surgical evaluation. The surgeon will determine eligibility through pulmonary function tests, ability to stimulate your diaphragm, and arterial blood gas levels. Eligibility may also be determined by your response to traditional respiratory strengthening exercises without a pacemaker.
  • History of mechanical ventilation dependence (six or more hours of invasive or non-invasive mechanical ventilation support daily for at least 21 days in duration

Exclusion criteria

  • Current participation in another treatment study (other than enzyme replacement therapy) directed at improving diaphragm function
  • Unable to complete pulmonary function testing

Treatment and study plan

Diaphragm conditioning via phrenic nerve stimulation

Other

Diaphragm pacing will be prescribed by the patient's clinical team.

Primary outcomes

  1. Off-ventilator Spontaneous Breathing (SB) at Baseline and Day 180

    Time frame: Baseline, Day 180

    The patient will undergo an initial trial of unassisted breathing with the diaphragm pacer turned on. The duration of SB with pacing will be increased to tolerance, using a protocol. If the patient cannot initially complete at least 30-minute bouts of paced SB, then the focus of breathing trials will be to breathe with reduced support from the mechanical ventilator. These measures were generated utilizing ventilator chip data for SB that has been averaged.

Secondary outcomes

  1. Maximal Inspiratory Pressure (MIP) at Baseline and Day 180

    Time frame: Baseline, Day 180

    MIP will be measured with a manometer connected to the airway opening of the subject, which occludes the airway and prevents airflow. A nose clip will be used to prevent leakage and the subject is instructed to suck air from the tube with as much force as possible. Measurements will be obtained with the subject sitting upright. Transdiaphragmatic pressure (Pdi) may be calculated with esophageal and gastric manometry during MIP. The measurement will be taken three times and the best value will be reported.

  2. Change in Resting Breathing Pattern

    Time frame: Day 180

    Resting ventilatory flow and timing will be recorded with a pneumotachograph and pressure transducer connected to the airway opening, to calculate minute ventilation. If a patient routinely uses MV throughout the day, the sensing equipment can be placed in series to the breathing tubes. Breathing pattern will be measured for a minimum of ten minutes.

  3. Diaphragm Electromyogram (EMG) at Day 180

    Time frame: Day 180

    This activity reflects the activity of the diaphragm and phrenic nerve. The wires that are implanted for diaphragm pacemaker will be connected to a computer and recording equipment to monitor the activity of the diaphragm muscle during breathing at the lowest level of ventilator assistance. This EMG data is measured in units of microvolts per second and expressed as a percentage of the level of diaphragm EMG activity recorded during MIP maneuvers.

Other outcomes

  1. Hours Per Day of Diaphragm Pacing

    Time frame: 180 days

    Number of hours used per day diaphragm pacing occurred by subjects

  2. Magnetic Stimulation

    Time frame: 180 Days

    EMG response to supramaximal bilateral stimulation of the phrenic nerves.

  3. Severe Respiratory Insufficiency Questionnaire

    Time frame: 180 days

    Patient reported measure of impact of respiratory insufficiency on functional mobility

  4. Forced Expiratory Flow

    Time frame: 180 days

    Peak expiratory flow obtained during voluntary cough

Sponsors and collaborators

Lead sponsor

University of Florida

Other

Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Registry information

Important dates

Study start
2013
Primary completion
2022
Study completion
2023
First posted
Feb 3, 2015
Registry last updated
Aug 1, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.